Faculty Opinions recommendation of Pathologic heterogeneity persists in early active multiple sclerosis lesions.

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.

Download Full-text

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1

Journal of Neuroimmunology ◽

10.1016/s0165-5728(02)00182-0 ◽

2002 ◽

Vol 129 (1-2) ◽

pp. 205-215 ◽

Cited By ~ 62

Author(s):

Xuan Feng ◽

Anthony L Petraglia ◽

Michael Chen ◽

Paul V Byskosh ◽

Markus D Boos ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Stimulated Genes ◽

Low Expression ◽

Active Multiple Sclerosis

Download Full-text

Natalizumab for the treatment of highly active multiple sclerosis: risks and benefits

British Journal of Neuroscience Nursing ◽

10.12968/bjnn.2019.15.5.216 ◽

2019 ◽

Vol 15 (5) ◽

pp. 216-222

Author(s):

Nicola Daykin

Keyword(s):

Multiple Sclerosis ◽

Gold Standard ◽

Risk Profile ◽

Risks And Benefits ◽

Highly Active ◽

History Of ◽

The Uk ◽

Highly Active Multiple Sclerosis ◽

Active Multiple Sclerosis

This article discusses the history of natalizumab (Tysabri), the first monoclonal antibody used to treat multiple sclerosis. It reviews how the medication's difficult beginnings and controversial past have changed how this treatment is monitored. The article looks at the role of clinicians in maintaining patient safety, the benefits and risk profile of this treatment and ways of optimising practice to provide gold standard nationalised natalizumab services throughout the UK.

Download Full-text

Highly active multiple sclerosis: An update

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2019.01.039 ◽

2019 ◽

Vol 30 ◽

pp. 215-224 ◽

Cited By ~ 22

Author(s):

Cindy Díaz ◽

Luis Alfonso Zarco ◽

Diego M. Rivera

Keyword(s):

Multiple Sclerosis ◽

Highly Active ◽

Highly Active Multiple Sclerosis ◽

Active Multiple Sclerosis

Download Full-text

Elevated D-dimer as an immediate response to alemtuzumab treatment

Multiple Sclerosis Journal ◽

10.1177/1352458520904277 ◽

2020 ◽

Vol 27 (1) ◽

pp. 151-154 ◽

Cited By ~ 1

Author(s):

Jana Libertinova ◽

Eva Meluzinova ◽

Eva Nema ◽

Petra Rockova ◽

Martin Elisak ◽

...

Keyword(s):

Multiple Sclerosis ◽

Adverse Reactions ◽

Low Molecular Weight ◽

Frequent Adverse Event ◽

Highly Active ◽

Thrombotic Complications ◽

Multiple Sclerosis Patients ◽

Highly Active Multiple Sclerosis ◽

D Dimer ◽

Active Multiple Sclerosis

Alemtuzumab as a treatment of highly active multiple sclerosis causes a rapid decrease in inflammatory activity due the lysis of immune cells. Subsequent cytokine release determines the infusion-associated reaction that is a frequent adverse event of alemtuzumab treatment. Recently, serious cardiovascular and thrombotic adverse reactions following alemtuzumab infusion have been described. In our study, the dynamics of coagulation parameters were analyzed in 13 multiple sclerosis patients treated with alemtuzumab. An immediate, significant increase in the level of D-dimer was observed after the first administration of alemtuzumab. This observation provides evidence of coagulation activation and the potential risk of thrombotic complications with this therapy. Prophylactic low molecular weight heparin pretreatment maybe considered in patients receiving alemtuzumab.

Download Full-text